Sareum Announces Collaboration with Schering
News Nov 21, 2005
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Schering AG, Germany.
The aim of the collaboration is for Sareum to provide protein structure determination capabilities to accelerate drug discovery research at Schering.
Sareum will utilise its expertise in high throughput protein expression, purification and structure determination to demonstrate how Schering’s potential drug candidates interact with their target protein receptor.
In return, Sareum will receive research fees and success milestone payments.
Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are delighted that Schering has chosen Sareum as their partner in protein structure determination."
"This is a further important collaboration that Sareum has signed with a major international pharmaceutical company."
"Revenues generated in collaborations such as this are valuable sources of financial support for our in-house cancer research programs."
"We look forward to successful delivery of this project to Schering and to closing additional partnerships such as this."
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE